Strategy for “Detoxification” of a Cancer-Derived Histone Mutant Based on Mapping Its Interaction with the Methyltransferase PRC2
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The histone methyltransferase PRC2 plays a central role in genomic stability and cellular development. Consequently, its misregulation has been implicated in several cancers. Recent work has shown that a histone H3 mutant, where the PRC2 substrate residue Lys27 is replaced by methionine, is also associated with cancer phenotypes and functions as an inhibitor of PRC2. Here we investigate the mechanism of this PRC2 inhibition through kinetic studies and photo-cross-linking. Efficient inhibition is dependent on (1) hydrophobic lysine isosteres blocking the active site, (2) proximal residues, and (3) the H3 tail forming extensive contacts with the EZH2 subunit of PRC2. We further show that naturally occurring post-translational modifications of the same H3 tail, both proximal and distal to K27M, can greatly diminish the inhibition of PRC2. These results suggest that this potent gain of function mutation may be “detoxified” by modulating alternate chromatin modification pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our previous work indicates that the presence of several histone posttranslational modifications in the H3 tail, both proximal and distal to K27, was able to neutralize the toxic effect of the K27M mutation (5).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We and others previously showed that K-to-M oncohistones transform the histone H3 proteins into potent inhibitors of specific lysine methyltransferase enzymes (4-7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies showed that the K27M mutation found in pediatric glioma is sufficient to transform histone H3 into a potent inhibitor of enzymatic activity of PRC2 (4, 5, 7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Self-citationThe Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
Lowary, P. T., & Widom, J. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1494 · Cited by 1,778
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345
Self-citationRole of the polycomb protein EED in the propagation of repressive histone marks
Margueron, R., Justin, N., Ohno, K., Sharpe, M. L., Son, J., Drury III, W. J., Voigt, P., Martin, S. R., Taylor, W. R., De Marco, V., et al. (2009) · Nature · doi:10.1038/nature08398 · Cited by 1,196
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Simon, J. A., & Lange, C. A. (2008) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2008.07.010 · Cited by 855
Research works printed but not linked: 2
- Wu G.; Broniscer A.; McEachron T. A.; Lu C.; Paugh B. S.; Becksfort J.; Qu C.; Ding L.; Huether R.; Parker M.; et al. St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project. Nat. Genet. 2012, 44, 251.22286216
- Copeland R. A. Reversible Inhibitors. In Enzymes; John Wiley & Sons, Inc.: Hoboken, NJ, 2002; pp 266– 304.
Cited by
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
Grasso, C. S., Tang, Y., Truffaux, N., Berlow, N. E., Liu, L., Debily, M.-A., Quist, M. J., Davis, L. E., Huang, E. C., Woo, P. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3855 · Cited by 687
Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2
Justin, N., Zhang, Y., Tarricone, C., Martin, S. R., Chen, S., Underwood, E., De Marco, V., Haire, L. F., Walker, P. A., Reinberg, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11316 · Cited by 400
Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma
Nagaraja, S., Vitanza, N. A., Woo, P. J., Taylor, K. R., Liu, F., Zhang, L., Li, M., Meng, W., Ponnuswami, A., Sun, W., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.011 · Cited by 396
Histones: At the Crossroads of Peptide and Protein Chemistry
Müller, M. M., & Muir, T. W. (2015) · Chemical Reviews · doi:10.1021/cr5003529 · Cited by 247
Self-citationMechanism of Cross-talk between H2B Ubiquitination and H3 Methylation by Dot1L
Worden, E. J., Hoffmann, N. A., Hicks, C. W., & Wolberger, C. (2019) · Cell · doi:10.1016/j.cell.2019.02.002 · Cited by 236
Developmental origins and emerging therapeutic opportunities for childhood cancer
Filbin, M., & Monje, M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0383-9 · Cited by 223
PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism
Jain, S. U., Do, T. J., Lund, P. J., Rashoff, A. Q., Diehl, K. L., Cieslik, M., Bajic, A., Juretic, N., Deshmukh, S., Venneti, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09981-6 · Cited by 208
Self-citationMultiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma
Stafford, J. M., Lee, C.-H., Voigt, P., Descostes, N., Saldaña-Meyer, R., Yu, J.-R., Leroy, G., Oksuz, O., Chapman, J. R., Suarez, F., et al. (2018) · Science Advances · doi:10.1126/sciadv.aau5935 · Cited by 191
ISWI chromatin remodellers sense nucleosome modifications to determine substrate preference
Dann, G. P., Liszczak, G. P., Bagert, J. D., Müller, M. M., Nguyen, U. T. T., Wojcik, F., Brown, Z. Z., Bos, J., Panchenko, T., Pihl, R., et al. (2017) · Nature · doi:10.1038/nature23671 · Cited by 183
Self-citationHübner, J.-M., Müller, T., Papageorgiou, D. N., Mauermann, M., Krijgsveld, J., Russell, R. B., Ellison, D. W., Pfister, S. M., Pajtler, K. W., & Kool, M. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz058 · Cited by 161
H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2
Jain, S. U., Rashoff, A. Q., Krabbenhoft, S. D., Hoelper, D., Do, T. J., Gibson, T. J., Lundgren, S. M., Bondra, E. R., Deshmukh, S., Harutyunyan, A. S., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.028 · Cited by 159
Self-citationHistone H3 Mutations: An Updated View of Their Role in Chromatin Deregulation and Cancer
Lowe, B. R., Maxham, L., Hamey, J. J., Wilkins, M. R., & Partridge, J. F. (2019) · Cancers · doi:10.3390/cancers11050660 · Cited by 144
Erratum: Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
Grasso, C. S., Tang, Y., Truffaux, N., Berlow, N., Liu, L., Debily, M.-A., Quist, M. J., Davis, L. E., Huang, E., Woo, P. J., et al. (2015) · Nature Medicine · doi:10.1038/nm0715-827a · Cited by 138
Epigenomic Reprogramming as a Driver of Malignant Glioma
Phillips, R. E., Soshnev, A. A., & Allis, C. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.008 · Cited by 117
Self-citationHistone H3 mutations—a special role for H3.3 in tumorigenesis?
Kallappagoudar, S., Yadav, R. K., Lowe, B. R., & Partridge, J. F. (2015) · Chromosoma · doi:10.1007/s00412-015-0510-4 · Cited by 116
G-tract RNA removes Polycomb repressive complex 2 from genes
Beltran-Nebot, M., Tavares, M., Justin, N., Khandelwal, G., Ambrose, J. C., Foster, B. M., Worlock, K. B., Tvardovskiy, A., Kunzelmann, S., Herrero, J., et al. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0293-z · Cited by 116
Mutations in chromatin machinery and pediatric high-grade glioma
Lulla, R. R., Saratsis, A. M., & Hashizume, R. (2016) · Science Advances · doi:10.1126/sciadv.1501354 · Cited by 106
Oncohistone mutations enhance chromatin remodeling and alter cell fates
Bagert, J. D., Mitchener, M. M., Patriotis, A. L., Dul, B. E., Wojcik, F., Nacev, B. A., Feng, L., Allis, C. D., & Muir, T. W. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00738-1 · Cited by 104
Self-citationHistone H3 tail binds a unique sensing pocket in EZH2 to activate the PRC2 methyltransferase
Jani, K. S., Jain, S. U., Ge, E. J., Diehl, K. L., Lundgren, S. M., Müller, M. M., Lewis, P. W., & Muir, T. W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819029116 · Cited by 103
Self-citationOncohistones: drivers of pediatric cancers
Mohammad, F., & Helin, K. (2017) · Genes & Development · doi:10.1101/gad.309013.117 · Cited by 101
Jayaram, H., Hoelper, D., Jain, S. U., Cantone, N., Lundgren, S. M., Poy, F., Allis, C. D., Cummings, R., Bellon, S., & Lewis, P. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605523113 · Cited by 92
Self-citationFindlay, I. J., Iuliis, G. N. D., Duchatel, R. J., Jackson, E. R., Vitanza, N. A., Cain, J. E., Waszak, S. M., & Dun, M. D. (2021) · Oncogene · doi:10.1038/s41388-021-02102-y · Cited by 90
Structure, mechanism, and regulation of polycomb-repressive complex 2
Moritz, L., & Trievel, R. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.800367 · Cited by 88
Regulation of histone methylation by automethylation of PRC2
Wang, X., Long, Y., Paucek, R. D., Gooding, A. R., Lee, T., Burdorf, R. M., & Cech, T. R. (2019) · Genes & Development · doi:10.1101/gad.328849.119 · Cited by 87
Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets
Aziz‐Bose, R., & Monje, M. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000577 · Cited by 85
Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma
Long, W., Yang, Y., Chen, S., Cao, Q., Zhao, W., & Liu, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00495 · Cited by 79
Oncogenic Mechanisms of Histone H3 Mutations
Weinberg, D. N., Allis, C. D., & Lü, C. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026443 · Cited by 78
Self-citationPachocki, C. J., & Hol, E. M. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02630-8 · Cited by 71
Signal Transduction in Diffuse Intrinsic Pontine Glioma
Duchatel, R. J., Jackson, E. R., Alvaro, F., Nixon, B., Hondermarck, H., & Dun, M. D. (2019) · PROTEOMICS · doi:10.1002/pmic.201800479 · Cited by 72
Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas
Panwalkar, P., Tamrazi, B., Dang, D., Chung, C., Sweha, S. R., Natarajan, S. K., Pun, M. J., Bayliss, J. M., Ogrodzinski, M. P., Pratt, D. W., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc0497 · Cited by 66
Self-citationHistone H3 Mutations in Cancer
Wan, Y. C. E., Liu, J., & Chan, K. M. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0141-6 · Cited by 64
Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation
Tatavosian, R., Duc, H. N., Huynh, T. N., Fang, D., Schmitt, B., Shi, X., Deng, Y., Phiel, C. J., Yao, T., Zhang, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04455-7 · Cited by 64
Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma
Wierzbicki, K., Ravi, K., Franson, A. T., Bruzek, A. K., Cantor, E., Harris, M. K., Homan, M. J., Marini, B. L., Kawakibi, A. R., Ravindran, R., et al. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0877-0 · Cited by 64
Activation and regulation of H2B-Ubiquitin-dependent histone methyltransferases
Worden, E. J., & Wolberger, C. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.05.009 · Cited by 63
Emerging roles of telomeric chromatin alterations in cancer
Cacchione, S., Biroccio, A., & Rizzo, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1030-5 · Cited by 52
Ehteda, A., Simon, S., Franshaw, L., Giorgi, F. M., Liu, J., Joshi, S. M., Rouaen, J. R. C., Pang, C. N. I., Pandher, R., Mayoh, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108994 · Cited by 51
A histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreading
Shan, C., Wang, J., Xu, K., Chen, H., Yue, J., Andrews, S. J., Moresco, J. J., Yates, J. R., Nagy, P. L., Tong, L., et al. (2016) · eLife · doi:10.7554/elife.17903 · Cited by 49
Lee, J. C., Solomon, D. A., & Tihan, T. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2349-9 · Cited by 49
Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies
Weisbrod, L. J., Anand, T., Vengoji, R., Shonka, N., Jain, M., Ho, W. S., Batra, S. K., & Salehi, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216876 · Cited by 48
Therapeutic Targets in Diffuse Midline Gliomas—An Emerging Landscape
Hayden, E., Holliday, H., Lehmann, R. J., Khan, A., Tsoli, M., Rayner, B. S., & Ziegler, D. S. (2021) · Cancers · doi:10.3390/cancers13246251 · Cited by 45
PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor
Diehl, K. L., Ge, E. J., Weinberg, D. N., Jani, K. S., Allis, C. D., & Muir, T. W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911775116 · Cited by 44
Self-citationOncohistones: Hijacking the Histone Code
Sahu, V., & Lü, C. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-102521 · Cited by 43
Xia, J., Li, J., Tian, L., Ren, X., Liu, C., & Liang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00047 · Cited by 43
Oncohistones: Exposing the nuances and vulnerabilities of epigenetic regulation
Mitchener, M. M., & Muir, T. W. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.07.008 · Cited by 41
Self-citationHistone Lysine-to-Methionine Mutations Reduce Histone Methylation and Cause Developmental Pleiotropy
Sanders, D., Qian, S., Fieweger, R. A., Lü, L., Dowell, J. A., Denu, J. M., & Zhong, X. (2017) · PLANT PHYSIOLOGY · doi:10.1104/pp.16.01499 · Cited by 41
Sundriyal, S., Chen, P. B., Lubin, A., Lueg, G. A., Li, F., White, A., Malmquist, N. A., Vedadi, M., Scherf, A., & Fuchter, M. J. (2017) · MedChemComm · doi:10.1039/c7md00052a · Cited by 38
Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma
Zhang, Q., Yang, L., Liu, Y. H., Wilkinson, J. E., & Krainer, A. R. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add8280 · Cited by 38
Surprising phenotypic diversity of cancer-associated mutations of Gly 34 in the histone H3 tail
Lowe, B. R., Yadav, R. K., Henry, R. A., Schreiner, P. A., Matsuda, A., Fernandez, A. G., Finkelstein, D., Campbell, M., Kallappagoudar, S., Jablonowski, C. M., et al. (2021) · eLife · doi:10.7554/elife.65369 · Cited by 38
Leszczyńska, K. B., Jayaprakash, C., Kaminska, B., & Mieczkowski, J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.742561 · Cited by 37
Lewis, N., Klein, R. H., Kelly, C., Yee, J. Q., & Knoepfler, P. S. (2022) · Epigenetics & Chromatin · doi:10.1186/s13072-022-00447-6 · Cited by 33
Gadais, C., Devillers, E., Gasparik, V., Chelain, E., Pytkowicz, J., & Brigaud, T. (2018) · ChemBioChem · doi:10.1002/cbic.201800088 · Cited by 32
Funato, K., & Tabar, V. S. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050143 · Cited by 30
Mechanism of cancer: Oncohistones in action
Qiu, L., Hu, X., Jing, Q., Zeng, X., Chan, K. M., & Han, J. (2018) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2018.04.004 · Cited by 29
Mendez, F., Núñez, F. J., Garcia-Fabiani, M. B., Haase, S., Carney, S. V., Gauss, J. C., Becher, O. J., Lowenstein, P. R., & Castro, M. G. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz218 · Cited by 27
Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy
Graham, M. S., & Mellinghoff, I. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197193 · Cited by 27
DNA binding by polycomb-group proteins: searching for the link to CpG islands
Owen, B. M., & Davidovich, C. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac290 · Cited by 25
Recognition of cancer mutations in histone H3K36 by epigenetic writers and readers
Klein, B. J., Krajewski, K., Restrepo, S., Lewis, P. W., Strahl, B. D., & Kutateladze, T. G. (2018) · Epigenetics · doi:10.1080/15592294.2018.1503491 · Cited by 24
Self-citationBailey, C. P., Figueroa, M., Mohiuddin, S., Zaky, W. T., & Chandra, J. (2018) · Bioengineering · doi:10.3390/bioengineering5040088 · Cited by 22
Gadais, C., Rosa, N. S., Chelain, E., Pytkowicz, J., & Brigaud, T. (2016) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201601318 · Cited by 22
Biophysical characterization of histone H3.3 K27M point mutation
Hetey, S., Boros-Oláh, B., Kuik-Rózsa, T., Li, Q., Karányi, Z., Szabó, Z., Roszik, J., Szalóki, N., Vámosi, G., Tóth, K., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.133 · Cited by 21
Huchedé, P., Leblond, P., & Castets, M. (2022) · Biomedicines · doi:10.3390/biomedicines10061311 · Cited by 20
Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas
Fernando, D., Ahmed, A. U., & Williams, B. R. G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1347694 · Cited by 19
Brown, Z. Z., Müller, M. M., Kong, H. E., Lewis, P. W., & Muir, T. W. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500085 · Cited by 17
Self-citationPhoto-Cross-Linking To Delineate Epigenetic Interactome
Zhang, Z., Lin, J., Liu, Z., Tian, G., Li, X., Jing, Y., Li, X., & Li, X. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c06135 · Cited by 17
Characterization of H3.3K36M as a tool to study H3K36 methylation in cancer cells
Sankaran, S. M., & Gozani, O. (2017) · Epigenetics · doi:10.1080/15592294.2017.1377870 · Cited by 17
Advances on Epigenetic Drugs for Pediatric Brain Tumors
Skouras, P., Markouli, M., Strepkos, D., & Piperi, C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220922150456 · Cited by 16
Groves, A. P., & Cooney, T. M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1089898 · Cited by 15
Pediatric high-grade glioma: A heterogeneous group of neoplasms with different molecular drivers
Giangaspero, F., Gianno, F., Antonelli, M., Ferretti, E., Massimino, M., & Arcella, A. (2018) · Glioma · doi:10.4103/glioma.glioma_27_18 · Cited by 15
Leszczyńska, K. B., Freitas-Huhtamäki, A., Jayaprakash, C., Dźwigońska, M., Vitorino, F. N. D. L., Horth, C., Wojnicki, K., Gielniewski, B., Szadkowska, P., Kaza, B., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113707 · Cited by 14
Janna, A., Davarinejad, H., Joshi, M., & Couture, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00600 · Cited by 13
Structural basis of nucleosomal H4K20 methylation by methyltransferase SET8
Shi, L., Huang, L., Long, H., Song, A., & Zhou, Z. (2022) · The FASEB Journal · doi:10.1096/fj.202101821r · Cited by 13
A Structural Perspective on Gene Repression by Polycomb Repressive Complex 2
Liu, X. (2020) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-58971-4_17 · Cited by 12
A patent review of EZH2 inhibitors from 2017 and beyond
Wan, G., Feng, H., Su, C., Zhu, Y., Zhang, L., Zhang, Q., & Yu, L. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2206018 · Cited by 12
Isenegger, P. G., Josephson, B., Gaunt, B., Davy, M., Gouverneur, V., Baldwin, A. J., & Davis, B. G. (2023) · Nature Protocols · doi:10.1038/s41596-022-00800-9 · Cited by 11
Yang, K., & Greenberg, M. M. (2018) · ChemBioChem · doi:10.1002/cbic.201800559 · Cited by 11
Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas
Lu, V. M., & Daniels, D. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-8104-5_6 · Cited by 10
Miró-Pina, C., Charmant, O., Giovannetti, M., de Vanssay, A., Frapporti, A., Humbert, A., Lhuillier‐Akakpo, M., Chevreux, G., Arnaiz, O., & Duharcourt, S. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1048 · Cited by 10
Rechberger, J. S., Power, B. T., Power, E. A., Nesvick, C. L., & Daniels, D. J. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2177531 · Cited by 9
Chromatin structure related to oncogenesis
Matsumoto, S., Horikoshi, N., Takizawa, Y., & Kurumizaka, H. (2023) · Cancer Science · doi:10.1111/cas.15850 · Cited by 8
Krist, D. T., & Statsyuk, A. V. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00625 · Cited by 8
H3.1K27M-induced misregulation of the TONSOKU-H3.1 pathway causes genomic instability
Yuan, W., Huang, Y.-C., LeBlanc, C., Poulet, A., Vitorino, F. N. D. L., Valsakumar, D., Dean, R., Garcia, B. A., van Wolfswinkel, J. C., Voigt, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58892-2 · Cited by 7
Zhang, Y., Justin, N., Wilson, J. R., & Gamblin, S. J. (2016) · Science · doi:10.1126/science.aaf6236 · Cited by 7
Supramolecular protein polymers using mini-ferritin Dps as the building block
Pacheco, M. R., Jacinto, J. P., Penas, D., Calmeiro, T., Almeida, A. V., Colaço, M., Fortunato, E., Jones, N. C., Hoffmann, S. V., Pereira, M. M. A., et al. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob01702g · Cited by 7
Diffuse intrinsic pontine glioma: Insights into oncogenesis and opportunities for targeted therapy
Groves, A. P., Bandopadhayay, P., & Cooney, T. M. (2023) · Pediatric Hematology Oncology Journal · doi:10.1016/j.phoj.2023.02.003 · Cited by 4
Brown, Z. Z., Müller, M. M., Kong, H. E., Lewis, P. W., & Muir, T. W. (2015) · Angewandte Chemie · doi:10.1002/ange.201500085 · Cited by 4
Self-citationGregorc, J., Lensen, N., Chaume, G., Iskra, J., & Brigaud, T. (2026) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6c00904 · Cited by 4
Chemical methods for studying the crosstalk between histone H2B ubiquitylation and H3 methylation
Ai, H., Peng, S., & Li, J. (2021) · Journal of Peptide Science · doi:10.1002/psc.3381 · Cited by 3
Kinetic Resolution of Epimeric Proteins Enables Stereoselective Chemical Mutagenesis
Ablat, G., Lawton, N., Alam, R., Haynes, B. A., Hossain, S., Hicks, T., Evans, S. L., Jarvis, J. A., Nott, T. J., Isaacson, R. L., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c07103 · Cited by 3
An E2 ubiquitin-conjugating enzyme links diubiquitinated H2B to H3K27M oncohistone function
Jiao, A. L., Sendinc, E., Zee, B. M., Wallner, F., & Shi, Y. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416614121 · Cited by 3
Reich, T. J., Clark, P. A., Baguette, A., Lempiäinen, J. K., Russo, C., Rashoff, A. Q., Do, T. J., Garcia, B. A., Kleinman, C. L., Jabado, N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.18.665585 · Cited by 3
Self-citationCapdevielle, C. (2018) · theses.fr (ABES) · doi:10.70675/61a11795ze624z4e25za249z1a5a7240c3f9 · Cited by 3
Polycomb Repressive Complex 2 in Oncology
Guo, Y., Yu, Y., & Wang, G. G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-45654-1_9 · Cited by 2
Liu, N., & Zhu, B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809737-3.00010-6 · Cited by 2
Peptide-based inhibitors of epigenetic proteins
Hintzen, J. C. J., & Mecinović, J. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.04.004 · Cited by 2
Assembling Ternary Dead-End Complex for Covalent Trapping of Protein Lysine Methyltransferases
Zong, Y., Zhang, N., Lin, J., Li, Z., Zou, Y., Chaudhuri, R., & Luo, M. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c14571 · Cited by 1
Transcriptional and epigenetic regulatory mechanisms in glioblastoma stem cells
Bressan, R. B., & Pollard, S. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814085-7.00010-6 · Cited by 1
The dark matter of diffuse intrinsic pontine gliomas: an update
Grill, J., Debily, M.-A., Varlet, P., Plessier, A., Dret, L. L., Beccaria, K., Puget, S., & Castel, D. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1560262 · Cited by 1
Tokodai, Y., & Yakushiji, F. (2019) · ChemBioChem · doi:10.1002/cbic.201900212 · Cited by 1
Molecular mechanism of residue-specific nucleosome acetylation
Müller, M., Kolesnikova, O., Doudin, M., Thomae, A. W., Sparr, A. C., Krause, S., Hoffmann, T., Becker, P. B., & Eustermann, S. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.09.019 · Cited by 1
Reversible cyanovinylcarbazole-based polymer gel via photo-cross-linking reaction
Cha, Y., Choi, Y., Choi, H., Park, H., Kim, J. H., & Jung, J. H. (2017) · Supramolecular chemistry · doi:10.1080/10610278.2017.1392021 · Cited by 1
Metadata
- Authors
- Brown, Z. Z., Müller, M. M., Jain, S. U., Allis, C. D., Lewis, P. W., & Muir, T. W.
- Affiliations
- Princeton University (US)
- Princeton University , , , ,
- University of Wisconsin–Madison (US)
- Rockefeller University (US)
- Corresponding author
- Muir, Tom W.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-09-02
- Volume
- 136
- Issue
- 39
- Pages
- 13498-13501
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- PMC
- PMC4183613
- OpenAlex
- W2314376783
- Cited by
- 111
- References
- 19
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 8 · 2023: 8 · 2022: 12 · 2021: 9 · 2020: 9 · 2019: 18 · 2018: 11 · 2017: 13 · 2016: 7 · 2015: 5 · 2014: 1
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of the American Chemical Society (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- National Institute of General Medical Sciences (R01 GM107047, R37-GM086868)
- STARR foundation (I6-A614)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Keywords
- H3K27M mutation, polycomb repressive complex 2, EZH2, histone methyltransferase inhibition, cancer, protein-protein interaction, photocrosslinking, enzyme kinetics, chromatin modification, gain-of-function mutations
- MeSH terms
- Enzyme Inhibitors, HeLa Cells, Histones, Humans, Kinetics, Models, Molecular, Mutation, Neoplasms, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.